Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 4
2020 2
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W. Chae YK, et al. Among authors: viveiros p. J Thorac Oncol. 2019 Oct;14(10):1807-1817. doi: 10.1016/j.jtho.2019.06.016. Epub 2019 Jun 22. J Thorac Oncol. 2019. PMID: 31238177 Free article.
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients.
Schroeder BA, Zhang Y, Smythe KS, Desai P, Thomas A, Viveiros P, Alexiev BA, Obeidin F, Chen EY, Cranmer LD, Wagner MJ, Jones RL, Campbell JS, Pierce RH, He Q, Pollack SM. Schroeder BA, et al. Among authors: viveiros p. Cancers (Basel). 2022 Mar 2;14(5):1290. doi: 10.3390/cancers14051290. Cancers (Basel). 2022. PMID: 35267598 Free PMC article.
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.
Silva SB, Pereira AAL, Marta GN, de Barros Lima KML, de Freitas TB, Matutino ARB, de Azevedo Souza MCL, de Azevedo RGMV, de Viveiros PAH, da Silva Lima JM, Filassi JR, de Andrade Carvalho H, Piato JRM, Mano MS. Silva SB, et al. Among authors: de viveiros pah. Breast. 2018 Apr;38:39-44. doi: 10.1016/j.breast.2017.11.012. Epub 2017 Dec 7. Breast. 2018. PMID: 29223797
Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy.
Lee D, Park J, Choi H, Gim G, Cho S, Kim L, Oh Y, Kang CY, Kim Y, Tan D, de Viveiros PAH, Chae YK. Lee D, et al. Among authors: de viveiros pah. Heliyon. 2021 Sep 2;7(9):e07916. doi: 10.1016/j.heliyon.2021.e07916. eCollection 2021 Sep. Heliyon. 2021. PMID: 34568594 Free PMC article.
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
Chae YK, Kim WB, Davis AA, Park LC, Anker JF, Simon NI, Rhee K, Song J, Cho A, Chang S, Ko T, Oh M, Bhave M, Viveiros P. Chae YK, et al. Among authors: viveiros p. Transl Lung Cancer Res. 2020 Aug;9(4):1015-1028. doi: 10.21037/tlcr-20-148. Transl Lung Cancer Res. 2020. PMID: 32953481 Free PMC article.
11 results